Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03876522 · ClinicalTrials.gov registry record
Natural History and Functional Status Study of Patients With Lafora Disease
A clinical trial, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- 33
- Enrollment target
NCT03876522: Completed study, sponsored by Ionis Pharmaceuticals.
NCT03876522 is a clinical trial that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 33 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03876522 has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- 33 participants
- Enrollment target
Study Summary
A natural history and functional status study to characterize the clinical disease course in Lafora disease patients using standardized, quantitative evaluations and to identify useful biomarkers and clinical outcome measures for use in future Lafora treatment studies.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2019-01-09 |
| Est. Completion | 2022-04-01 |
What the finished NCT03876522 record still lists
NCT03876522 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 33 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03876522 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03876522 about?
NCT03876522 is a clinical study titled "Natural History and Functional Status Study of Patients With Lafora Disease". A natural history and functional status study to characterize the clinical disease course in Lafora disease patients using standardized, quantitative evaluations and to identify useful biomarkers and clinical outcome measures for use in future Lafora treatment studies.
What is the current status of trial NCT03876522?
This trial is currently completed. The enrollment target is 33 participants. The study started on 2019-01-09. Estimated completion is 2022-04-01.
Who is sponsoring clinical trial NCT03876522?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI